{"id":922,"date":"2019-04-24T13:50:58","date_gmt":"2019-04-24T11:50:58","guid":{"rendered":"https:\/\/www.velitnb.com\/?p=922"},"modified":"2019-04-25T15:29:54","modified_gmt":"2019-04-25T13:29:54","slug":"biosimilars-generics","status":"publish","type":"post","link":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/","title":{"rendered":"Portfolio Management Strategies for Biosimilars &amp; Generics"},"content":{"rendered":"\n<figure class=\"wp-block-image\"><img loading=\"lazy\" decoding=\"async\" width=\"861\" height=\"206\" src=\"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar.png\" alt=\"\" class=\"wp-image-923\" srcset=\"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar.png 861w, https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar-300x72.png 300w, https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar-768x184.png 768w\" sizes=\"auto, (max-width: 861px) 100vw, 861px\" \/><\/figure>\n\n\n\n<p><strong>3<\/strong><sup><strong>rd <\/strong><\/sup><strong>annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES)<\/strong><br><\/p>\n\n\n\n<p>Our president, Nicola Travierso, will participate as expert speaker.<br>Case Study<br><em>Product Portfolio: Activities and Preparation<\/em><\/p>\n\n\n\n<p>\u2022 Understanding \u201cCommodities\u201d, difficult products to become  <br>biosimilars, medical devices, food supplement and SFMP <\/p>\n\n\n\n<p>\u2022 Evaluating the selection criteria and life cycles of  <br>each product <\/p>\n\n\n\n<p>\u2022 Maturity\nand Substitution<\/p>\n","protected":false},"excerpt":{"rendered":"<p>3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity&hellip; <br \/> <a class=\"read-more\" href=\"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/\">Leggi tutto<\/a><\/p>\n","protected":false},"author":2,"featured_media":923,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-922","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-senza-categoria"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 4.9.10 - aioseo.com -->\n\t<meta name=\"description\" content=\"3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Filippo Borri\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 4.9.10\" \/>\n\t\t<meta property=\"og:locale\" content=\"it_IT\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Velit | Online - Nano-Biopahrmaceutical\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Portfolio Management Strategies for Biosimilars &amp; Generics - Velit | Online\" \/>\n\t\t<meta property=\"og:description\" content=\"3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png\" \/>\n\t\t<meta property=\"og:image:width\" content=\"276\" \/>\n\t\t<meta property=\"og:image:height\" content=\"117\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2019-04-24T11:50:58+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2019-04-25T13:29:54+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Portfolio Management Strategies for Biosimilars &amp; Generics - Velit | Online\" \/>\n\t\t<meta name=\"twitter:description\" content=\"3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#blogposting\",\"name\":\"Portfolio Management Strategies for Biosimilars & Generics - Velit | Online\",\"headline\":\"Portfolio Management Strategies for Biosimilars &amp; Generics\",\"author\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/author\\\/filippo11\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/Biosimilar.png\",\"width\":861,\"height\":206},\"datePublished\":\"2019-04-24T13:50:58+02:00\",\"dateModified\":\"2019-04-25T15:29:54+02:00\",\"inLanguage\":\"it-IT\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#webpage\"},\"articleSection\":\"Senza categoria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.velitnb.com\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/category\\\/senza-categoria\\\/#listItem\",\"name\":\"Senza categoria\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/category\\\/senza-categoria\\\/#listItem\",\"position\":2,\"name\":\"Senza categoria\",\"item\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/category\\\/senza-categoria\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#listItem\",\"name\":\"Portfolio Management Strategies for Biosimilars &amp; Generics\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#listItem\",\"position\":3,\"name\":\"Portfolio Management Strategies for Biosimilars &amp; Generics\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/category\\\/senza-categoria\\\/#listItem\",\"name\":\"Senza categoria\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/#organization\",\"name\":\"Velit | Online\",\"description\":\"Nano-Biopahrmaceutical\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/wp-content\\\/uploads\\\/2019\\\/12\\\/cropped-logo_velit.png\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#organizationLogo\",\"width\":276,\"height\":117},\"image\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/author\\\/filippo11\\\/#author\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/author\\\/filippo11\\\/\",\"name\":\"Filippo Borri\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/cb8004c69b5d930eea49a2c3e7184e3e9b08bf14051c3aa9bafab4e178b12dc6?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Filippo Borri\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#webpage\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/\",\"name\":\"Portfolio Management Strategies for Biosimilars & Generics - Velit | Online\",\"description\":\"3rd annual Portfolio Management Strategies for Biosimilars & Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \\u2022 Understanding \\u201cCommodities\\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \\u2022 Evaluating the selection criteria and life cycles of each product \\u2022 Maturity\",\"inLanguage\":\"it-IT\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/author\\\/filippo11\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/author\\\/filippo11\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/Biosimilar.png\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#mainImage\",\"width\":861,\"height\":206},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/index.php\\\/2019\\\/04\\\/24\\\/biosimilars-generics\\\/#mainImage\"},\"datePublished\":\"2019-04-24T13:50:58+02:00\",\"dateModified\":\"2019-04-25T15:29:54+02:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/#website\",\"url\":\"https:\\\/\\\/www.velitnb.com\\\/\",\"name\":\"Velit | Online\",\"description\":\"Nano-Biopahrmaceutical\",\"inLanguage\":\"it-IT\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.velitnb.com\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Portfolio Management Strategies for Biosimilars & Generics - Velit | Online","description":"3rd annual Portfolio Management Strategies for Biosimilars & Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity","canonical_url":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#blogposting","name":"Portfolio Management Strategies for Biosimilars & Generics - Velit | Online","headline":"Portfolio Management Strategies for Biosimilars &amp; Generics","author":{"@id":"https:\/\/www.velitnb.com\/index.php\/author\/filippo11\/#author"},"publisher":{"@id":"https:\/\/www.velitnb.com\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar.png","width":861,"height":206},"datePublished":"2019-04-24T13:50:58+02:00","dateModified":"2019-04-25T15:29:54+02:00","inLanguage":"it-IT","mainEntityOfPage":{"@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#webpage"},"isPartOf":{"@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#webpage"},"articleSection":"Senza categoria"},{"@type":"BreadcrumbList","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/www.velitnb.com#listItem","position":1,"name":"Home","item":"https:\/\/www.velitnb.com","nextItem":{"@type":"ListItem","@id":"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/#listItem","name":"Senza categoria"}},{"@type":"ListItem","@id":"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/#listItem","position":2,"name":"Senza categoria","item":"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/","nextItem":{"@type":"ListItem","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#listItem","name":"Portfolio Management Strategies for Biosimilars &amp; Generics"},"previousItem":{"@type":"ListItem","@id":"https:\/\/www.velitnb.com#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#listItem","position":3,"name":"Portfolio Management Strategies for Biosimilars &amp; Generics","previousItem":{"@type":"ListItem","@id":"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/#listItem","name":"Senza categoria"}}]},{"@type":"Organization","@id":"https:\/\/www.velitnb.com\/#organization","name":"Velit | Online","description":"Nano-Biopahrmaceutical","url":"https:\/\/www.velitnb.com\/","logo":{"@type":"ImageObject","url":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#organizationLogo","width":276,"height":117},"image":{"@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/www.velitnb.com\/index.php\/author\/filippo11\/#author","url":"https:\/\/www.velitnb.com\/index.php\/author\/filippo11\/","name":"Filippo Borri","image":{"@type":"ImageObject","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/cb8004c69b5d930eea49a2c3e7184e3e9b08bf14051c3aa9bafab4e178b12dc6?s=96&d=mm&r=g","width":96,"height":96,"caption":"Filippo Borri"}},{"@type":"WebPage","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#webpage","url":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/","name":"Portfolio Management Strategies for Biosimilars & Generics - Velit | Online","description":"3rd annual Portfolio Management Strategies for Biosimilars & Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity","inLanguage":"it-IT","isPartOf":{"@id":"https:\/\/www.velitnb.com\/#website"},"breadcrumb":{"@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#breadcrumblist"},"author":{"@id":"https:\/\/www.velitnb.com\/index.php\/author\/filippo11\/#author"},"creator":{"@id":"https:\/\/www.velitnb.com\/index.php\/author\/filippo11\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/04\/Biosimilar.png","@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#mainImage","width":861,"height":206},"primaryImageOfPage":{"@id":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/#mainImage"},"datePublished":"2019-04-24T13:50:58+02:00","dateModified":"2019-04-25T15:29:54+02:00"},{"@type":"WebSite","@id":"https:\/\/www.velitnb.com\/#website","url":"https:\/\/www.velitnb.com\/","name":"Velit | Online","description":"Nano-Biopahrmaceutical","inLanguage":"it-IT","publisher":{"@id":"https:\/\/www.velitnb.com\/#organization"}}]},"og:locale":"it_IT","og:site_name":"Velit | Online - Nano-Biopahrmaceutical","og:type":"article","og:title":"Portfolio Management Strategies for Biosimilars &amp; Generics - Velit | Online","og:description":"3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity","og:url":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/","og:image":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png","og:image:secure_url":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png","og:image:width":276,"og:image:height":117,"article:published_time":"2019-04-24T11:50:58+00:00","article:modified_time":"2019-04-25T13:29:54+00:00","twitter:card":"summary_large_image","twitter:title":"Portfolio Management Strategies for Biosimilars &amp; Generics - Velit | Online","twitter:description":"3rd annual Portfolio Management Strategies for Biosimilars &amp; Generics, 25-27 September 2019 Barcelona (ES) Our president, Nicola Travierso, will participate as expert speaker.Case StudyProduct Portfolio: Activities and Preparation \u2022 Understanding \u201cCommodities\u201d, difficult products to become biosimilars, medical devices, food supplement and SFMP \u2022 Evaluating the selection criteria and life cycles of each product \u2022 Maturity","twitter:image":"https:\/\/www.velitnb.com\/wp-content\/uploads\/2019\/12\/cropped-logo_velit.png"},"aioseo_meta_data":{"post_id":"922","title":null,"description":null,"keywords":null,"keyphrases":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2023-02-11 22:02:28","updated":"2025-06-04 05:30:56","seo_analyzer_scan_date":null},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.velitnb.com\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/\" title=\"Senza categoria\">Senza categoria<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">&raquo;<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tPortfolio Management Strategies for Biosimilars &amp; Generics\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/www.velitnb.com"},{"label":"Senza categoria","link":"https:\/\/www.velitnb.com\/index.php\/category\/senza-categoria\/"},{"label":"Portfolio Management Strategies for Biosimilars &amp; Generics","link":"https:\/\/www.velitnb.com\/index.php\/2019\/04\/24\/biosimilars-generics\/"}],"_links":{"self":[{"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/posts\/922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/comments?post=922"}],"version-history":[{"count":4,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/posts\/922\/revisions"}],"predecessor-version":[{"id":932,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/posts\/922\/revisions\/932"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/media\/923"}],"wp:attachment":[{"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/media?parent=922"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/categories?post=922"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.velitnb.com\/index.php\/wp-json\/wp\/v2\/tags?post=922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}